99697-24-2

Basic information

• Product Name: 24-norursodeoxycholic acid
• Synonyms: 24-norursodeoxycholic acid;(3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid;3α,7β-Dihydroxy-24-nor-5β-cholan-23-oic Acid;Norursodeoxycholic Acid
• CAS NO: 99697-24-2
• Molecular Formula: C₂₃H₃₈O₄
• Molecular Weight: 378.55
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Steroids
• Mol File: 99697-24-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 536.7°Cat760mmHg
• Flash Point: 292.4°C
• Appearance: /
• Density: 1.142g/cm³
• Vapor Pressure: 9.33E-14mmHg at 25°C
• Refractive Index: 1.546
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Ethanol (Slightly), Methanol (Slightly)
• PKA: 4.71±0.10(Predicted)
• CAS DataBase Reference: 24-norursodeoxycholic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 24-norursodeoxycholic acid(99697-24-2)
• EPA Substance Registry System: 24-norursodeoxycholic acid(99697-24-2)

Safety Data

• Hazardous Substances Data: 99697-24-2(Hazardous Substances Data)

Usage

Chemical Properties

Off-White to Pale Yellow Solid

Uses

Ursodeoxycholic Acid (U850000) derivative. 24-norUrsodeoxycholic acid is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

InChI:InChI=1/C23H38O4/c1-13(10-20(26)27)16-4-5-17-21-18(7-9-23(16,17)3)22(2)8-6-15(24)11-14(22)12-19(21)25/h13-19,21,24-25H,4-12H2,1-3H3,(H,26,27)/t13-,14+,15-,16-,17+,18+,19+,21+,22+,23-/m1/s1

Upstream product

• 118316-07-7 3α,7β-diformyloxy-24-nor-5β-cholan-23-nitrile 
• 6058-15-7 (R)-4-((3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-bis(formyloxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoic acid 
• 128-13-2 ursodeoxycholic acid 
• 118316-12-4 3α,7β-dihydroxy-24-nor-5β-cholan-23-nitrile 
• 1380159-64-7 3α,7β-dihydroxy-24-nor-5β-cholan-23-oic acid potassium salt 

Downstream Products

• 141417-57-4 23-p-toluenesulfoxy-24-nor-5β-cholane-3α,7β-diol 
• 141541-00-6 sodium 3α,7β-dihydroxy-24-nor-5β-cholane-23-sulfonate 

Relevant articles and documents

CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES

13073PTWO 56 ABSTRACT The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases. 5

Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.